PeptideSearch

Emideltide

Very early research

Get notified when the evidence changes.

The research is at the earliest stage – mostly cells in a lab dish. It is far too early to say much.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-07-24

Also called DSIP / Delta sleep-inducing peptide / Delta-sleep-inducing peptide / Emideltide acetate / Emideltide free base

Emideltide, better known as DSIP, is a nine amino acid peptide (sequence WAGGDASGE, UniProt P01158) isolated in 1977 by Swiss researchers from the cerebral venous blood of rabbits during induced sleep. It has been studied for sleep regulation, chronic insomnia, narcolepsy, opioid withdrawal, stress response and pain modulation. The FDA treated the free base and the acetate salt as separate bulk drug substances.

The basics

What is it?
A short peptide, nine amino acids long, first pulled out of rabbit blood in 1977 during sleep. Its other name, delta sleep-inducing peptide, describes what researchers hoped it did.
What do we know?
It has been studied in people for sleep problems, including one placebo-controlled study in chronic insomnia that reported people slept more of the time they were in bed and fell asleep faster.
What do we still not know?
The name implies a settled role, and it is not settled. No clear receptor has been established, and whether the body makes it, what it does, what it binds to and how it moves through the body are all still debated. The gene for it has never been found, in rabbits or anywhere else.

Official status: Declined for the 503A bulks list · Checked 2026-07-24

Can a doctor prescribe this?

Small pharmacy (503A)
An FDA panel said no
Large outsourcing facility (503B)
Never put forward to FDA

An FDA advisory panel voted against recommending emideltide for the 503A bulks list in July 2026. It was the only one of the seven peptides reviewed that the panel declined.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

What FDA actually looked at

FDA reviewed this peptide for Opioid withdrawal, chronic insomnia, and narcolepsy. That is a narrower question than the uses this peptide is usually marketed for.

What happens next

The advisory panel voted against Emideltide. FDA has not said whether it will consider it again, and there is no scheduled next step.

Emideltide was the only one of the seven peptides the panel declined to recommend. Members who voted no pointed to weak evidence that it works and to how poorly the substance itself is characterized. Nothing prevents a new nomination later, but nothing is currently moving.

The July 2026 review covered the 503A list only. No 503B review has been scheduled.

503B is the separate list that would allow large-scale supply. It has not moved for any of the seven peptides.

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

What has happened so far

  1. 24 July 2026503A

    FDA proposed that Emideltide NOT be included on the 503A Bulks List. The advisory committee agreed — the only one of the seven peptides where it did.

    FDA briefing documentnot yet verified against primary source

  2. 24 July 2026503A

    The committee voted 7-6 with one abstention AGAINST recommending emideltide (delta sleep-inducing peptide) for the 503A Bulks List. It was the meeting's only rejection.

    6–7, 1 abstained

    FDA briefing documentnot yet verified against primary source

  3. 16 April 2026503A

    FDA published a Federal Register notice announcing a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 at the White Oak campus, to consider seven peptides for the 503A Bulks List.

    Federal Registernot yet verified against primary source

We'll email you when a new study, trial or status change lands for Emideltide. Unsubscribe in one click.